EP0028092A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
A radiolabeled antibody composition, a kit for making same and a cancer or tumor-detection kit employing the composition
Assignee: Summa Medical Corp
•
Filing: 1980-10-14
•
Granted: —
•
Expires: 2000-10-14
Abstract
Abstract Tc-99m labeled antibody compositions and kits for oreparing them and using them for in vivo diagnostic purposes are provided. Cancer or tumor sites producing hCG or hCG-derivatives are detected by scintigraphy, after administering anti-hCG or anti-hCG derivatives, by administering an antibody composition specific to the anti-hCG or its derivatives, the said antibody composition being tagged with one of the labeling isotopes. To increase sensitivity of detection, extra sites for the labeled composition can be obtained by administering an unlabeled antibody composition specific to the anti-hCG or its derivatives, followed by a second antibody composition specific to the first antibody, the second antibody composition being tagged with one of the labeling isotopes.
Inventors
- 👤 Scott W. Burchiel
- 👤 David R. Crockford
- 👤 Buck A. Rhodes
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-24 15:23
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/02; A61K51/04; A61K51/08; A61K51/10; A61K2123/00; Y; Y10; Y10S; Y10S530/00; Y10S530/806; Y10S530/827; Y10S530/828
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
121 words
A composition of matter comprising in admixture with an excipient a radiolabeled antibody characterised in that the radiolabel thereof is technetium-99m and the labeled antibody is reactive with an antigen, which is anti-human chorionic gonadotropin, anti-human chorionic gonadotropin beta or a mixture thereof or which is a tumor-specific antigen other than hCG or hCG-beta when the antibody is other than anti-hCG and anti hCG-beta, either directly or via a second antibody that is reactive directly with the said antigen in which case the labeled antibody is reactive with the second antibody directly or through a further antibody or chain of mutually reactive antibodies, the antibodies at the ends of the chain being reactive with the labeled antibody and second antibody respectively.
Claim 2
Dependent Claim
121 words
A composition of matter comprising in admixture with an excipient a radiolabeled antibody characterised in that the radiolabel thereof is technetium-99m and the labeled antibody is reactive with an antigen, which is anti-human chorionic gonadotropin, anti-human chorionic gonadotropin beta or a mixture thereof or which is a tumor-specific antigen other than hCG or hCG-beta when the antibody is other than anti-hCG and anti hCG-beta, either directly or via a second antibody that is reactive directly with the said antigen in which case the labeled antibody is reactive with the second antibody directly or through a further antibody or chain of mutually reactive antibodies, the antibodies at the ends of the chain being reactive with the labeled antibody and second antibody respectively.
Claim 3
Dependent Claim
74 words
A kit for forming a composition useful in identifying cancer cells or malignant tumors in vivo, characterised by a preparation including an antibody other than anti-hCG, anti-hCG-beta or anti-hCG-like material which is reactive with cancer cell or tumor-specific antigen, or an antibody against anti-hCG, anti-hCG-beta or anti-hCG-like material, and reagents including a radiolabeling constituent comprising technetium-99m, for mixing with said antibody to produce an administratable, physiologically-acceptable aqueous solution of said antibody labeled with technetium-99m.
Claim 4
Dependent Claim
74 words
A kit for forming a composition useful in identifying cancer cells or malignant tumors in vivo, characterised by a preparation including an antibody other than anti-hCG, anti-hCG-beta or anti-hCG-like material which is reactive with cancer cell or tumor-specific antigen, or an antibody against anti-hCG, anti-hCG-beta or anti-hCG-like material, and reagents including a radiolabeling constituent comprising technetium-99m, for mixing with said antibody to produce an administratable, physiologically-acceptable aqueous solution of said antibody labeled with technetium-99m.
Claim 5
Dependent Claim
87 words
A diagnostic kit for in vivo detection of cancer cells or malignant tumors, characterised by a plurality of antibody preparations for administrating sequentially to a patient, the first antibody preparation for administration being reactive with the cancer cell or tumor-specific antigen, each of the other antibody preparations being reactive with the preparation to be administered before it, and reagents including a radiolabeling constituent comprising technetium-99m for mixing with the last antibody preparation to be administered to produce a physiologically-acceptable aqueous solution of this antibody labeled with technetium-99m.
Claim 6
Dependent Claim
87 words
A diagnostic kit for in vivo detection of cancer cells or malignant tumors, characterised by a plurality of antibody preparations for administrating sequentially to a patient, the first antibody preparation for administration being reactive with the cancer cell or tumor-specific antigen, each of the other antibody preparations being reactive with the preparation to be administered before it, and reagents including a radiolabeling constituent comprising technetium-99m for mixing with the last antibody preparation to be administered to produce a physiologically-acceptable aqueous solution of this antibody labeled with technetium-99m.
Claim 7
Dependent Claim
33 words
A kit according to claim 3, characterised by comprising two antibodies, namely anti-hCG, anti-hCG-beta or anti-hCG-like matter; and antibody against the anti-hCG, anti-hCG-beta or anti-hCG-like matter; and reagents for labeling the latter antibody.
Claim 8
Dependent Claim
32 words
A kit according to claim 3 or claim 4, characterised by the reagents including a source of technetium-99m and a physiologically-acceptable reducing agent for reducing teclmetium (VII) to the (IV) oxidation state.
Claim 9
Dependent Claim
38 words
A kit according to claim 5, characterised by including a column of material capable of binding technetium in the (IV) oxidation state and of releasing the technetium when contacted with a solution of the antibody to be labeled.
Claim 10
Dependent Claim
26 words
A kit according to claim 6, characterised by including an ion exchange resin capable of removing pertechnetate ion from a solution of the technetium-99m labeled antibody.
Claim 11
Dependent Claim
121 words
A diagnostic method for detecting cancer cells or malignant tumors in vivo, characterised by administering a physiologically-acceptable preparation of an antibody against a cancer cell or tumor-specific antigen and then administering either a physiologically-acceptable radiolabeled preparation of another antibody reactive with the first antibody or a series of sequentially- administered, physiologically-acceptable preparations of antibodies each of which is reactive with the antibody preparation administered before it, when the last-administered preparation is radiolabeled, and the radiolabeled preparation is radiolabeled with technetium-99m, and thereafter monitoring the biodistribution of the labeled preparation by scintigraphy, administration of the preparation or preparations following administration of the first antibody being timed to allow metabolization of substantially all the preceding antibody not bound to cancer cells or tumors.
Claim 12
Dependent Claim
121 words
A diagnostic method for detecting cancer cells or malignant tumors in vivo, characterised by administering a physiologically-acceptable preparation of an antibody against a cancer cell or tumor-specific antigen and then administering either a physiologically-acceptable radiolabeled preparation of another antibody reactive with the first antibody or a series of sequentially- administered, physiologically-acceptable preparations of antibodies each of which is reactive with the antibody preparation administered before it, when the last-administered preparation is radiolabeled, and the radiolabeled preparation is radiolabeled with technetium-99m, and thereafter monitoring the biodistribution of the labeled preparation by scintigraphy, administration of the preparation or preparations following administration of the first antibody being timed to allow metabolization of substantially all the preceding antibody not bound to cancer cells or tumors.
Claim 13
Dependent Claim
49 words
A method according to claim 8 for detecting cells or tumors which produce hCG, hCG-beta or hCT-like matter, characterised in that the first antibody preparation is selected from anti-hCG, anti-hCG-beta, or a mixture thereof, and the antibody preparation which is next administered comprises anti-anti-hCG, anti-anti-hCG-beta or a mixture thereof.
Claim 14
Dependent Claim
18 words
A method according to claim 9 , characterised in that the onti-anti-hCG-type antibody preparation is radiolabeled with technetium-99m.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.